Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Literature DB >> 9113436

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

D D Breimer¹, M Danhof.

Abstract

Mesh：

Year: 1997 PMID： 9113436 DOI： 10.2165/00003088-199732040-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

26 in total

1. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

Authors: A L van Steveninck; S Verver; H C Schoemaker; M S Pieters; R Kroon; D D Breimer; A F Cohen
Journal: Clin Pharmacol Ther Date: 1992-10 Impact factor: 6.875

2. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis.

Authors: L T Breimer; A G Burm; M Danhof; P J Hennis; A A Vletter; J W de Voogt; J Spierdijk; J G Bovill
Journal: Clin Pharmacokinet Date: 1991-06 Impact factor: 6.447

3. Efficacy measures: surrogates or clinical outcomes?

Authors: J W Blue; W A Colburn
Journal: J Clin Pharmacol Date: 1996-09 Impact factor: 3.126

4. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

Authors: J D Unadkat; F Bartha; L B Sheiner
Journal: Clin Pharmacol Ther Date: 1986-07 Impact factor: 6.875

5. Comparative pharmacokinetics of coumarin anticoagulants. X. Relationship between distribution, elimination, and anticoagulant action of warfarin.

Authors: A Yacobi; L B Wingard; G Levy
Journal: J Pharm Sci Date: 1974-06 Impact factor: 3.534

Review 6. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.

Authors: M Danhof; J W Mandema; A Hoogerkamp; R A Mathôt
Journal: Eur J Drug Metab Pharmacokinet Date: 1993 Jan-Mar Impact factor: 2.441

7. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

Authors: J W Mandema; M T Kuck; M Danhof
Journal: Br J Pharmacol Date: 1992-01 Impact factor: 8.739

8. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats.

Authors: R A Mathôt; B C Van den Aarsen; W Soudijn; D D Breimer; A P Ijzerman; M Danhof
Journal: J Pharmacol Exp Ther Date: 1995-04 Impact factor: 4.030

Review 9. Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors: J Urquhart
Journal: Clin Pharmacokinet Date: 1994-09 Impact factor: 6.447

10. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.

Authors: T D Egan; C F Minto; D J Hermann; J Barr; K T Muir; S L Shafer
Journal: Anesthesiology Date: 1996-04 Impact factor: 7.892

25 in total

1. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors: H Derendorf; B Meibohm
Journal: Pharm Res Date: 1999-02 Impact factor: 4.200

Review 2. Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors: Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal: Invest New Drugs Date: 2003-05 Impact factor: 3.850

3. Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding.

Authors: Michael Weiss; Wonku Kang
Journal: Pharm Res Date: 2004-02 Impact factor: 4.200

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

1. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

2. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis.

3. Efficacy measures: surrogates or clinical outcomes?

4. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

5. Comparative pharmacokinetics of coumarin anticoagulants. X. Relationship between distribution, elimination, and anticoagulant action of warfarin.

Review 6. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.

7. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

8. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats.

Review 9. Role of patient compliance in clinical pharmacokinetics. A review of recent research.

10. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.

1. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Review 2. Pharmacokinetic-pharmacodynamic guided trial design in oncology.

3. Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding.

Review 4. Role of modelling and simulation: a European regulatory perspective.

Review 5. A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.

6. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

7. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Review 8. Integrated pharmacokinetics and pharmacodynamics in drug development.

9. Concepts and challenges in quantitative pharmacology and model-based drug development.

10. PK/PD modelling and beyond: impact on drug development.